Social Media Ideas for 340B Drug Pricing

<![CDATA[The Economics of the 340B Drug Pricing Program: Strategic Imperatives for the Life Sciences Industry in 2026...

The Future of 340B: New Bills Offer Competing Solutions to Modernize the 340B Drug Discount Program

The 340B Program Hit $100 Billion in 2025: Has It Become Too Big to Reform?

By Adam J. Fein, Ph.D.The 340B Drug Pricing Program continues to redefine the meaning of "skyrocketing." For 2025, discounted purchases under the 340B program reached an astound...

340B at a Crossroads: What Health Systems Need to Know About Senator Cassidy's Reform Proposal

On June 25, 2026, Senate HELP Committee Chairman Bill Cassidy (R-LA) released a sweeping legislative discussion draft titled the 340B Drug Pricing Integrity and Affordability for P...

Hospitals Cry Foul After Eli Lilly Withholds 340B Discounts

Eli Lilly made good on its threat to withhold 340B drug discounts from hospitals that refused to submit claims data. Hospital groups are calling the policy unlawful, arguing that t...

<![CDATA[Eli Lilly to Deny 340B Drug Pricing Due to Claims-Data Policy: Report ]]>

The Hidden Cost of 340B for Employers and Health Plans

By Adam J. Fein, Ph.D.For years, the controversy surrounding the 340B Drug Pricing Program has centered on hospitals, manufacturers, and contract pharmacies. But employers and h...

Tampa General Hospital sues Eli Lilly over pulled 340B discounts

The drugmaker's decision to rescind 340B discounts to hospitals that do not submit requested claims data has raised prices at Tampa General Hospital by 25% to 50% on average, it wr...

Hospitals allege contracted CVS Health subsidiaries pocketed their 340B savings

Lawsuits filed by nonprofit hospitals accuse the company's pharmacy benefit manager, specialty pharmacy and third-party administrator of working together to artificially depress ra...

If 340B Helps, Why Are Hospitals Fighting Transparency?

The Trump administration is considering a pilot program that could bring much-needed transparency to the 340B drug discount program, created by Congress to help hospitals and clini...

Explore the 340B Ecosystem

The vision of the 340B Drug Pricing Program is to... The post Explore the 340B Ecosystem appeared first on SRM Technologies - Global Partner for Digital, Embedded and Product Engin...

Minnesota’s 340B Hospitals Make One Billion More From 340B Than They Spend on Uncompensated Care (rerun)

This week, we’re rerunning some popular posts while we prepare for today’s live video webinar: 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders....

Hospitals irate after Eli Lilly follows through on 340B ultimatum

The drugmaker stopped paying 340B discounts to hospitals that didn’t comply with its new paperwork requirements late last week. Hospitals are urging HRSA to step in.

This Week in 340B: July 7 – July 13, 2026

Senate and House Lawmakers Unveil Competing 340B Reform Proposals

By Abdie Santiago —

Hospitals Take CVS to Court Over Alleged $250M 340B Scheme

Three health systems — Mount Sinai, Michigan Medicine and the University of Kansas Health System — are suing CVS Health, alleging its pharmacy benefit manager diverted roughly $250...

Eli Lilly issues data sharing ultimatum to 340B hospitals

Select hospitals have refused to share data to prove they’re not double-dipping drug discounts, Lilly said. Hospitals, which have until Monday to comply, are urging the government...

This Week in 340B: May 26 – June 1, 2026

Medicare drug price rule may target under-the-skin Keytruda and Opdivo

For 2029, a federal rule proposes closing a "loophole" that protects medicines transitioning from intravenous administration from price protection.

This Week in 340B: June 30 – July 6, 2026

The Truth About 340B - and Why Drug Companies Want It Weakened

Medicare Fraud, Kickbacks Rampant at 340B Hospitals

The 340B Drug Discount Program was created to help low-income patients. Instead, it too often helps multibillion dollar “non-profit” hospitals to fund ad campaigns, pad executive p...

The 340B Contract Pharmacy Market in 2026: A Maturing Industry Dominated by Big Chains and PBMs

By Adam J. Fein, Ph.D. and Greis Kapexhiu It’s time for Drug Channels Institute’s latest exclusive analysis of the 340B contract pharmacy market, which continues to boom along with...

Cassidy's new plan to overhaul 340B: Rebates, contract pharmacy limits and more changes

A legislative discussion draft shared Thursday by the Senate HELP chairman includes rebates, contract pharmacy limits, narrowed definitions and other proposals.